Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma
Authors:
- Rolf StahelRSRolf Stahel
- Verena NiggemeierVNVerena Niggemeier
- Christoph GublerCGChristoph Gubler
- Daniel FranzenDFDaniel Franzen
- 1 June 2013
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 80 (3) , 347-349
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Skin Toxicities Compromise Prolonged Pemetrexed TreatmentJournal of Thoracic Oncology, 2011
- Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancerGut, 2011
- Pemetrexed in advanced non-small cell lung cancerExpert Opinion on Drug Safety, 2010
- Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case reportLung Cancer, 2009
- Malignant pleural mesothelioma: current treatments and emerging drugsExpert Opinion on Emerging Drugs, 2009
- Pemetrexed-Induced Typhlitis in Non-small Cell Lung CancerJournal of Thoracic Oncology, 2008
- Pemetrexed Maintenance Therapy in Patients with Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2006
- Neutropenic enterocolitis in adults: systematic analysis of evidence qualityEuropean Journal of Haematology, 2005
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004
- Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.Journal of Clinical Oncology, 1997